Type1 Diabetes
Conditions
Brief summary
The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes. One group will receive aldesleukin and the other a placebo.
Detailed description
Investigators know that the longer people with diabetes can produce their own insulin, the better it is for the control of their blood glucose levels and long-term complications. People get type 1 diabetes because their immune system, the part of the body, which helps fight infections, mistakenly attacks and destroys the beta cells in the pancreas that produce insulin. As the immune system destroys these insulin-producing cells, the body's own ability to produce insulin decreases and diabetes develops. At diagnosis, there are usually a small number of beta cells (10-20%) left in the pancreas, which still produce small amounts of insulin. This is called 'beta cell function' and it is assessed by measuring C-peptide, which is a protein made by the pancreas when insulin is produced. Most people with type 1 diabetes eventually stop producing insulin themselves, this may occur rapidly in a few months, or more slowly over several years. New treatments preserving insulin production could improve management of diabetes. This could be done by using drugs acting on cells of the immune system. In type 1 diabetes, there is an imbalance between cells of the immune system, and there is evidence that one protein produced by our body, called Interleukin-2, could help in resetting the balance between those cells. It is important to start this treatment soon after diagnosis because this when there is the best chance of saving the beta cells still left in the pancreas.
Interventions
DRUGAldesleukin
PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion
OTHERPlacebo
sterile diluent used for the aldesleukin preparation and 5% glucose
Sponsors
Oxford Clinical Trials Research Unit (OCTRU)
Centre for Statistics in Medicine, Oxford
Juvenile Diabetes Research Foundation
Wellcome Trust
University of Oxford
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Have given written informed consent to participate or assent with parental consent 2. Be aged 6-18 years 3. Be diagnosed with T1D (Type 1 Diabetes) (at least one autoantibody positive), requiring insulin treatment 4. Be within 6 weeks from diagnosis of T1D (at screening) 5. Have a random C-peptide \> 200 pmol/l 6. Normal full blood count
Exclusion criteria
1. Non-type 1 diabetes (type 2 or monogenic diabetes) and secondary diabetes 2. Pre-existing autoimmune disease (excluding type 1 diabetes) 3. Hypersensitivity to aldesleukin or any of the excipients 4. History of severe cardiac disease (NYHA Class III or IV) 5. History of malignancy within the past 5 years (with the exception of adequately treated basal or squamous cell carcinoma or cervical carcinoma in situ) 6. Clinically significant abnormal laboratory values (out of range and associated with clinical symptoms or signs) in haematology, biochemistry, thyroid, liver and kidney function 7. Pre-existing severe major organ dysfunction or seizure disorders 8. Participation in another clinical trial (CTIMP) within 4 months prior to screening 9. Females who are pregnant, lactating or intend to get pregnant during the study 10. Females of childbearing potential who are unwilling or unable to comply with contraceptive advice and regular pregnancy testing throughout the trial 11. Sexually active males who are unwilling or unable to comply with contraceptive advice 12. Current use of immunosuppressive agents or steroids 13. Current treatment with hepatotoxic, nephrotoxic, myelotoxic, or cardiotoxic products 14. Active clinical infections - participants can be recruited after a minimum period of 48 h after last day of feeling unwell or last day of antibiotic/anti-viral treatment 15. Any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the participant ineligible for inclusion because of a safety concern 16. Children with compliance problems (families where the local investigators consider that problems with compliance may be an issue)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in slopes of DBS (Dried Blood Spot) C-peptide over the 6 month-treatment period between the active and placebo groups. | Weekly DBS C-peptide collected during the 6-month treatment period, and then monthly during the 6 months of follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety will be assessed at each visit (reported reactions using CTCAE grading v5.0) | At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment | Assessment of the most commonly reported reactions to low- or high-dose aldesleukin, namely influenza-like syndrome, skin reaction, diarrhoea, nausea using CTCAE grading v5.0 |
| Safety will be assessed at each visit (temperature in celsius) | At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment | Vital signs - temperature in celsius |
| Safety will be assessed at each visit (weight, in kilograms) | At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment | Vital signs - weight, in kilograms |
| Safety will be assessed at each visit (blood pressure: systolic/diastolic) | At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment | Vital signs - blood pressure: systolic/diastolic |
| Safety will be assessed at each visit (heart rate: bpm) | At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment | Vital signs - heart rate: bpm |
| Change in Treg, Teff and NK56bright cell frequencies and phenotypes from baseline | At baseline and then1, 2 , 3, 6 and 12 months from the beginning of treatment | — |
| Safety will be assessed at each visit total bilirubin - milligrams per deciliter (mg/dL) | At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment | Abnormal laboratory parameters liver function total bilirubin - milligrams per deciliter (mg/dL) |
| Safety will be assessed at each visit (urea and creatinine - mmol/L) | At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment | Abnormal laboratory parameters kidney function (urea and creatinine - mmol/L) |
| Safety will be assessed at each visit (full blood count - 109/L) | At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment | Abnormal laboratory parameters full blood count - 109/L |
| Changes in the absolute numbers of T, B and NK (Natural Killer) cells. | At baseline and then, 1, 2 , 3, 6 and 12 months from the beginning of treatment | — |
| Change in HbA1c and daily insulin requirements during the trial period. | HbA1c - At baseline and then 3,6 and 12 months Insulin dose data -Baseline and then 1, 2, 3, 6 and 12 months | — |
| Safety will be assessed at each visit (AST, ALT, ALP, GGT units per liter (U/L) | At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment | Abnormal laboratory parameters liver function (AST, ALT, ALP, GGT units per liter (U/L) |
Countries
United Kingdom
Outcome results
None listed